Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
about
DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down SyndromeSpecific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative SplicingDesign and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitorsA chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibitionIdentification of CLK1 Inhibitors by a Fragment-linking Based Virtual Screening.Catalyst-free synthesis of quinazolin-4-ones from (hetero)aryl-guanidines: application to the synthesis of pyrazolo[4,3-f]quinazolin-9-ones, a new family of DYRK1A inhibitors.Comparison of bioluminescent kinase assays using substrate depletion and product formation.Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2009.Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)Clk/STY (cdc2-like kinase 1) and Akt regulate alternative splicing and adipogenesis in 3T3-L1 pre-adipocytesPharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitorsHarmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A)Synthesis and SAR studies of novel 6,7,8-substituted 4-substituted benzyloxyquinolin-2(1H)-one derivatives for anticancer activityBenzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members.Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315.Activation, regulation, and inhibition of DYRK1A.Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?Pharmacology of Modulators of Alternative Splicing.DYRK1A inhibition as potential treatment for Alzheimer's disease.Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease.CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.A public-private partnership to unlock the untargeted kinome.Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Mechanism of dual specificity kinase activity of DYRK1A.Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.
P2860
Q26745413-EB441C19-4E2A-495A-83DB-09CBD1C6442FQ27666758-65205F32-A35C-445C-8F8B-15B964CEC7A7Q28541616-1141E537-425E-4F51-94D7-E9FB0F9C8771Q28828212-346F6BDF-33CF-4266-BC2A-BD0D706EF1FAQ30396689-8E3C4343-C7DC-4844-A69A-D858C588FA84Q30568278-77B50011-2BB8-464B-9471-73A45840FB2CQ33522759-73236CEC-478C-4E2C-BDF0-EAF245D83C14Q33710833-3B98A69D-C265-440B-A3A7-3BA7E92BB2BCQ33857859-F643E71A-DEC6-4072-94F1-70B5FB6BC5EEQ34544872-5EAE1B24-0A0B-4711-B975-F3B3E31A9679Q34621349-925E1BA9-9859-4C47-956E-DCF21D21933AQ34708624-9AB422D7-A164-4595-B2E7-97FAF78F6C94Q35111443-2907269E-A3DA-4688-AA1E-B777A827AAE9Q35877840-D3B9083E-47AF-4808-B526-CABE3F77E564Q36876032-747E4F53-856B-4BDD-92F7-69761824D586Q37815234-C5F81DAC-EE75-4BDF-92E0-B19E85B00D04Q38061634-9923576D-05FF-42E9-9F62-9A24D32057CEQ38776406-AFD705AD-2DA8-4D5B-9FF1-1F0B16216A7EQ38807264-79234086-3917-47B6-BF9F-6F1F3A3A5315Q38850493-00D327B8-1BBD-4413-85C6-6B0877664848Q42266393-D98D38CF-6700-4507-B9AA-83935B262666Q44090999-0A630686-8815-4A82-95BA-B1905FC501A3Q48001145-2ECDF373-BBF0-4673-B98E-37B8C71A744AQ50871004-C3A81D97-FBD7-4315-BE39-6A3E883AE51BQ54981975-0749508B-E67D-4AC4-98D7-D9DA6EAEB0A2
P2860
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Evaluation of substituted 6-ar ...... rs of cdc2-like kinases (Clk).
@ast
Evaluation of substituted 6-ar ...... rs of cdc2-like kinases (Clk).
@en
type
label
Evaluation of substituted 6-ar ...... rs of cdc2-like kinases (Clk).
@ast
Evaluation of substituted 6-ar ...... rs of cdc2-like kinases (Clk).
@en
prefLabel
Evaluation of substituted 6-ar ...... rs of cdc2-like kinases (Clk).
@ast
Evaluation of substituted 6-ar ...... rs of cdc2-like kinases (Clk).
@en
P2093
P2860
P1476
Evaluation of substituted 6-ar ...... rs of cdc2-like kinases (Clk).
@en
P2093
Cordelle Tanega
Craig J Thomas
David J Maloney
Douglas S Auld
James Inglese
Juan J Marugan
Paul Shinn
Tom Misteli
William Leister
P2860
P304
P356
10.1016/J.BMCL.2009.09.121
P407
P577
2009-10-03T00:00:00Z